|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] |
CTD |
PMID:9297556 PMID:9403342 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases activity |
ISO |
Deoxyguanosine analog results in decreased activity of MGMT protein |
CTD |
PMID:17880193 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
|
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 2:151,314,818...151,320,312
Ensembl chr 2:151,314,818...151,320,319
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions increases sulfation |
ISO |
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate |
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
EXP ISO |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein] [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein |
CTD |
PMID:12672554 PMID:15452191 PMID:19966059 |
|
NCBI chr 2:208,336,909...208,379,217
Ensembl chr 2:208,373,154...208,376,803
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16116186 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression decreases response to substance |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance |
ISO |
BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases response to substance decreases expression |
ISO |
NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA |
CTD |
PMID:16088125 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr13:60,846,458...60,849,061
Ensembl chr13:60,846,308...60,849,094
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] |
CTD |
PMID:15452191 |
|
NCBI chr 5:151,573,122...151,626,360
Ensembl chr 5:151,573,092...151,627,316
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
LOC103694381 |
lymphotoxin-beta |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr20:4,861,343...4,863,513
Ensembl chr20:4,861,335...4,863,198
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:22841775 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects expression |
ISO |
Azacitidine affects the expression of ADRB1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression |
ISO |
Azacitidine affects the expression of ADRB2 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Azacitidine results in increased expression of AFP mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Aggf1 |
angiogenic factor with G patch and FHA domains 1 |
increases expression |
ISO |
Azacitidine results in increased expression of AGGF1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:25,068,804...25,095,429
Ensembl chr 2:25,069,620...25,095,106
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of AHR mRNA [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]] |
CTD |
PMID:12927368 PMID:17682057 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ak5 |
adenylate kinase 5 |
increases expression |
ISO |
Azacitidine results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression |
ISO |
Azacitidine results in decreased expression of ALAD mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alb |
albumin |
decreases expression increases expression |
ISO |
Azacitidine results in decreased expression of ALB protein Azacitidine results in increased expression of ALB mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of ANXA1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
App |
amyloid beta precursor protein |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of APP promoter Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp5 |
aquaporin 5 |
decreases methylation increases expression multiple interactions |
ISO |
Azacitidine results in decreased methylation of AQP5 promoter Azacitidine results in increased expression of AQP5 protein [Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 |
|
NCBI chr 7:141,249,044...141,252,576
Ensembl chr 7:141,249,044...141,252,578
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions increases expression |
ISO |
[Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] |
CTD |
PMID:25953102 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone |
CTD |
PMID:18324645 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arhgap35 |
Rho GTPase activating protein 35 |
increases expression |
ISO |
Azacitidine results in increased expression of ARHGAP35 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:78,456,409...78,573,374
Ensembl chr 1:78,456,409...78,573,374
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
Art1 |
ADP-ribosyltransferase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ART1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:167,202,064...167,206,615
Ensembl chr 1:167,197,549...167,206,614
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ASB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:127,212,325...127,248,451
Ensembl chr 6:127,212,273...127,248,372
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
increases expression |
ISO |
Azacitidine results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP |
Azacitidine results in increased expression of BAD mRNA [Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA Azacitidine results in increased expression of BAK1 mRNA |
CTD |
PMID:21224363 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein] Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein |
CTD |
PMID:32278510 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions affects expression |
ISO |
[metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1 [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein |
CTD |
PMID:18443271 PMID:19148494 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l13 |
BCL2 like 13 |
increases expression |
ISO |
Azacitidine results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of BDNF mRNA Azacitidine results in decreased methylation of BDNF promoter Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA] |
CTD |
PMID:18184782 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Azacitidine results in decreased expression of BGLAP protein |
CTD |
PMID:18037191 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA Azacitidine results in increased expression of BIK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bmp15 |
bone morphogenetic protein 15 |
increases expression |
ISO |
Azacitidine results in increased expression of BMP15 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr X:17,016,831...17,021,894
Ensembl chr X:17,016,778...17,023,418
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25446377 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA Azacitidine results in increased expression of BOK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
|
|
G |
C3ar1 |
complement C3a receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of C3AR1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:155,681,767...155,691,240
Ensembl chr 4:155,684,029...155,690,869
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of CALCA promoter |
CTD |
PMID:19299654 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CALD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Casp3 |
caspase 3 |
affects expression increases expression multiple interactions |
ISO |
Azacitidine affects the expression of CASP3 protein Azacitidine results in increased expression of CASP3 mRNA [metacept-1 co-treated with Azacitidine] results in increased expression of CASP3 |
CTD |
PMID:18443271 PMID:19148494 PMID:23395740 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP8 mRNA |
CTD |
PMID:18082045 PMID:23395740 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions decreases expression |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter] Azacitidine results in decreased expression of CCNA1 mRNA |
CTD |
PMID:17698632 |
|
NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA Azacitidine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:18720364 PMID:20823114 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA Azacitidine results in increased expression of CCNB1 protein |
CTD |
PMID:18720364 PMID:20607034 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Azacitidine results in increased expression of CCND1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
affects methylation multiple interactions |
ISO |
Azacitidine affects the methylation of CCND2 promoter [Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA |
CTD |
PMID:17016690 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CCNG2 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762
|
|
G |
Cdh1 |
cadherin 1 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CDH1 promoter Azacitidine results in increased expression of CDH1 mRNA |
CTD |
PMID:17520682 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh2 |
cadherin 2 |
increases expression |
EXP |
Azacitidine results in increased expression of CDH2 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA Azacitidine analog results in increased expression of CDK1 protein |
CTD |
PMID:18324645 PMID:18720364 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK2 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK4 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA [Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A |
CTD |
PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Azacitidine results in increased expression of CDKN1C mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions decreases methylation affects methylation increases expression |
EXP ISO |
[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene] Azacitidine affects the methylation of CDKN2A gene Azacitidine results in increased expression of CDKN2A mRNA |
CTD |
PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases methylation multiple interactions affects response to substance |
ISO |
Azacitidine results in decreased methylation of CDKN2B promoter [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B CDKN2B promoter modified form affects the susceptibility to Azacitidine |
CTD |
PMID:17611569 PMID:19148494 PMID:19194470 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CEBPA promoter Azacitidine results in increased expression of CEBPA mRNA |
CTD |
PMID:19194470 PMID:27590069 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:27,072,259...27,080,863
Ensembl chr 6:27,072,166...27,080,856
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA |
CTD |
PMID:18720364 |
|
NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
|
|
G |
Cenpo |
centromere protein O |
increases expression |
ISO |
Azacitidine results in increased expression of CENPO mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:28,648,804...28,663,527
Ensembl chr 6:28,649,638...28,663,233
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein |
CTD |
PMID:19151599 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Azacitidine results in decreased expression of CHGA protein |
CTD |
PMID:20607034 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chit1 |
chitinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CHIT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:50,947,020...50,994,644
Ensembl chr13:50,974,872...50,994,643
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM2 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chst14 |
carbohydrate sulfotransferase 14 |
increases expression |
EXP |
Azacitidine results in increased expression of CHST14 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 3:110,734,105...110,736,162
Ensembl chr 3:110,734,105...110,736,162
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions increases expression |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA] Azacitidine results in increased expression of CIITA mRNA |
CTD |
PMID:18829986 PMID:20823114 |
|
NCBI chr10:5,212,621...5,260,641
Ensembl chr10:5,213,350...5,260,608
|
|
G |
Cldn10 |
claudin 10 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CLDN10 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:104,026,590...104,115,748
Ensembl chr15:104,026,601...104,115,748
|
|
G |
Cldn6 |
claudin 6 |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of CLDN6 mRNA Azacitidine results in decreased methylation of CLDN6 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter |
CTD |
PMID:18661270 |
|
NCBI chr10:12,999,256...13,002,860
Ensembl chr10:13,000,090...13,002,862
|
|
G |
Cldn8 |
claudin 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CLDN8 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr11:28,525,641...28,527,890
Ensembl chr11:28,525,643...28,527,890
|
|
G |
Cldn9 |
claudin 9 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of CLDN9 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter Azacitidine results in increased expression of CLDN9 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr10:13,003,010...13,004,441
Ensembl chr10:13,003,011...13,004,441
|
|
G |
Cnnm2 |
cyclin and CBS domain divalent metal cation transport mediator 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CNNM2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:266,530,421...266,651,292
Ensembl chr 1:266,530,477...266,649,398
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
increases expression |
ISO |
Azacitidine results in increased expression of COL14A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:95,054,877...95,274,073
Ensembl chr 7:95,074,236...95,273,298
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL9A3 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 3:176,102,287...176,124,839
Ensembl chr 3:176,102,351...176,124,306
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Azacitidine results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Azacitidine results in increased expression of CPE mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813
|
|
G |
Cplx1 |
complexin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] |
CTD |
PMID:19155497 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Creb3l4 |
cAMP responsive element binding protein 3-like 4 |
increases expression |
EXP |
Azacitidine results in increased expression of CREB3L4 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:189,596,657...189,602,243
Ensembl chr 2:189,595,415...189,602,143
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
Azacitidine results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Cryaa |
crystallin, alpha A |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAA protein |
CTD |
PMID:17105402 |
|
NCBI chr20:10,438,444...10,442,189
Ensembl chr20:10,438,444...10,442,187
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAB protein |
CTD |
PMID:17105402 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
EXP |
Azacitidine results in increased expression of CSF1 mRNA |
CTD |
PMID:17156202 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csn1s1 |
casein alpha s1 |
increases expression |
ISO |
Azacitidine results in increased expression of CSN1S1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:21,993,450...22,009,308
Ensembl chr14:21,993,427...22,009,308
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Azacitidine results in increased expression of CST3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:143,219,671...143,223,544
Ensembl chr 3:143,219,686...143,223,615
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CXCL12 promoter Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein |
CTD |
PMID:19748759 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] Azacitidine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] Azacitidine results in increased expression of CYP1A2 mRNA |
CTD |
PMID:12927368 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Azacitidine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12927368 PMID:27590069 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression |
ISO |
Azacitidine results in increased expression of CYP3A4 mRNA |
CTD |
PMID:27590069 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CYTH1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:107,197,983...107,281,285
Ensembl chr10:107,197,989...107,281,235
|
|
G |
Dapk1 |
death associated protein kinase 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of DAPK1 promoter |
CTD |
PMID:17557868 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dcn |
decorin |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] Azacitidine results in decreased expression of DCN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Des |
desmin |
increases expression multiple interactions |
EXP ISO |
Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dhx9 |
DExH-box helicase 9 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of DLK1 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX5 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 4:32,387,741...32,392,085
Ensembl chr 4:32,387,741...32,392,007
|
|
G |
Dlx6 |
distal-less homeobox 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX6 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:32,373,096...32,377,388
Ensembl chr 4:32,373,641...32,377,253
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases expression |
ISO EXP |
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein] [Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein |
CTD |
PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
decreases methylation multiple interactions decreases response to substance |
ISO |
Azacitidine results in decreased methylation of DPYD promoter [Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Azacitidine |
CTD |
PMID:15501990 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP6 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:19451745 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Efna3 |
ephrin A3 |
increases expression |
ISO |
Azacitidine results in increased expression of EFNA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:188,636,304...188,645,302
Ensembl chr 2:188,637,852...188,645,196
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Azacitidine results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Eno2 |
enolase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ENO2 protein |
CTD |
PMID:20607034 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ENTPD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:259,692,020...259,818,922
Ensembl chr 1:259,739,955...259,819,494
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ESR1 protein |
CTD |
PMID:22558281 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fam8a1 |
family with sequence similarity 8, member A1 |
increases expression |
ISO |
Azacitidine results in increased expression of FAM8A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:18,413,093...18,421,974
Ensembl chr17:18,415,629...18,421,861
|
|
G |
Faslg |
Fas ligand |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to FASLG protein |
CTD |
PMID:18829727 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of FBLN1 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:226,251,516...226,256,160
Ensembl chr 1:226,251,518...226,255,886
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FGF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
decreases expression |
ISO |
Azacitidine results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:45,039,488...45,275,141
Ensembl chr11:45,039,461...45,124,423
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein |
CTD |
PMID:18493985 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of FTL1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Azacitidine results in increased expression of FYN mRNA |
CTD |
PMID:21245298 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
ISO |
Azacitidine results in increased expression of GABRB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr14:38,631,192...39,112,598
Ensembl chr14:38,643,385...39,112,600
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of GADD45A promoter [Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein |
CTD |
PMID:19190346 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B] |
CTD |
PMID:18225533 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gata4 |
GATA binding protein 4 |
increases expression |
EXP |
Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein |
CTD |
PMID:18037191 |
|
NCBI chr15:46,386,703...46,458,679
Ensembl chr15:46,386,712...46,432,965
|
|
G |
Gbp2 |
guanylate binding protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
decreases expression |
ISO |
Azacitidine results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression |
ISO |
Azacitidine results in increased expression of GDF9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr10:38,782,519...38,793,238
Ensembl chr10:38,788,992...38,792,940
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression decreases expression |
EXP ISO |
Azacitidine results in increased expression of GJA1 protein Azacitidine results in decreased expression of GJA1 mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of GNG7 promoter |
CTD |
PMID:18219292 |
|
NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929
|
|
G |
Gpkow |
G patch domain and KOW motifs |
increases expression |
ISO |
Azacitidine results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:15,636,567...15,651,332
Ensembl chr X:15,636,563...15,651,332
|
|
G |
Gpnmb |
glycoprotein nmb |
decreases expression |
ISO |
Azacitidine results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of GRIN2B gene |
CTD |
PMID:18618247 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Guk1 |
guanylate kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of GUK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:45,535,617...45,552,455
Ensembl chr10:45,535,627...45,543,897
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein] |
CTD |
PMID:19394699 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
ISO |
Azacitidine results in increased expression of H1-0 protein |
CTD |
PMID:16006241 |
|
NCBI chr 7:120,260,776...120,262,636
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO EXP |
Azacitidine results in increased expression of H2AX protein Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:17991895 PMID:25015661 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
H3f4 |
H3.4 histone |
multiple interactions |
ISO |
Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr10:45,304,696...45,305,106
|
|
G |
H4f16 |
H4 histone 16 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr17:43,821,122...43,821,587
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
increases expression |
ISO |
Azacitidine results in increased expression of HGD mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:65,983,221...66,034,555
Ensembl chr11:65,983,221...66,034,573
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
ISO |
Azacitidine results in increased expression of HGF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression |
ISO |
Azacitidine results in increased expression of HHEX mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 1:256,101,994...256,107,581
Ensembl chr 1:256,101,903...256,107,649
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
Azacitidine results in increased expression of HMGA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:7,132,501...7,140,155
Ensembl chr20:7,136,007...7,138,980
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of HMGA2 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:65,159,944...65,275,408
Ensembl chr 7:65,159,944...65,275,408
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression multiple interactions |
ISO |
Azacitidine results in decreased expression of HMGB1 mRNA Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HNF1A promoter HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein |
CTD |
PMID:25953102 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases expression |
ISO |
Azacitidine results in increased expression of HNF4A mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] Azacitidine results in increased expression of HOXA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HPGD gene trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA] |
CTD |
PMID:19584167 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
Azacitidine affects the expression of HSD3B1 mRNA |
CTD |
PMID:18033690 |
|
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Azacitidine results in increased expression of ID1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
increases expression |
ISO |
Azacitidine results in increased expression of ID3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:154,489,603...154,491,172
Ensembl chr 5:154,489,590...154,491,223
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein |
CTD |
PMID:18829986 PMID:18945643 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] Azacitidine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Azacitidine results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Azacitidine results in increased expression of IL1B mRNA |
CTD |
PMID:17156202 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il4 |
interleukin 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of IL4 promoter |
CTD |
PMID:18158872 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
affects secretion affects methylation |
ISO |
Azacitidine affects the secretion of IL6 protein Azacitidine affects the methylation of IL6 promoter |
CTD |
PMID:18158872 PMID:18443271 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6r |
interleukin 6 receptor |
affects expression multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA [Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ISCA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:5,281,727...5,294,386
Ensembl chr17:5,281,727...5,294,384
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Itprid2 |
ITPR interacting domain containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ITPRID2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:66,593,767...66,631,143
Ensembl chr 3:66,593,934...66,631,723
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
EXP |
Azacitidine results in increased expression of KDR mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:136,027,923...136,053,268
Ensembl chr 5:136,027,934...136,053,210
|
|
G |
Kir3dl1 |
killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein Azacitidine results in decreased methylation of KIR3DL1 promoter |
CTD |
PMID:18945643 PMID:19394699 |
|
NCBI chr 1:73,306,564...73,345,009
Ensembl chr 1:73,307,569...73,344,955
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of KLF6 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT19 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Krt32 |
keratin 32 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT32 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:87,993,569...88,000,818
Ensembl chr10:87,993,551...88,000,534
|
|
G |
Krt8 |
keratin 8 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] Azacitidine results in increased expression of KRT8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects localization |
ISO |
Azacitidine affects the localization of LAMA1 protein |
CTD |
PMID:18033690 |
|
NCBI chr 9:115,916,907...116,042,123
Ensembl chr 9:115,916,907...116,042,123
|
|
G |
Lamb2 |
laminin subunit beta 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517
|
|
G |
Ldhb |
lactate dehydrogenase B |
increases expression |
ISO |
Azacitidine results in increased expression of LDHB mRNA |
CTD |
PMID:23437403 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lims1 |
LIM zinc finger domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of LIMS1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:27,895,981...28,004,767
Ensembl chr20:27,954,433...28,002,082
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LITAF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
|
|
G |
LOC100911664 |
uncharacterized LOC100911664 |
increases expression |
ISO |
Azacitidine results in increased expression of C6ORF62 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:42,256,971...42,268,607
Ensembl chr17:42,257,019...42,276,797
|
|
G |
LOC102553180 |
protocadherin alpha-1-like |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA1 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,824,891...29,839,850
|
|
G |
LOC686035 |
similar to heat shock 70kDa protein 6 (HSP70B) |
increases expression |
ISO |
Azacitidine results in increased expression of HSPA6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:89,408,703...89,411,500
|
|
G |
Ltb4r |
leukotriene B4 receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LTB4R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:34,449,299...34,453,352
Ensembl chr15:34,452,116...34,453,171
|
|
G |
Lyz2 |
lysozyme 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LYZ mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mad1l1 |
mitotic arrest deficient 1 like 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAD1L1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:16,410,083...16,721,232
Ensembl chr12:16,410,083...16,719,824
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:68,055,976...68,282,656
Ensembl chr 8:68,055,972...68,282,590
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr19:14,523,482...14,561,281
Ensembl chr19:14,523,554...14,561,278
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MDC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:3,405,017...3,419,831
Ensembl chr20:3,404,711...3,419,831
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Azacitidine results in increased expression of MDM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr X:156,650,389...156,713,813
Ensembl chr X:156,655,960...156,705,233
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression affects expression |
ISO |
Azacitidine results in increased expression of MEF2A Azacitidine affects the expression of MEF2A protein |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 1:128,207,715...128,341,681
Ensembl chr 1:128,209,971...128,341,263
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
affects expression increases expression |
ISO |
Azacitidine affects the expression of MEF2D protein Azacitidine results in increased expression of MEF2D |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 2:187,511,775...187,541,285
Ensembl chr 2:187,512,164...187,538,026
|
|
G |
Megf6 |
multiple EGF-like-domains 6 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MEGF6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:171,588,901...171,620,947
Ensembl chr 5:171,472,273...171,620,947
|
|
G |
Mesd |
mesoderm development LRP chaperone |
decreases expression |
EXP |
Azacitidine results in decreased expression of MESD protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:146,030,211...146,043,097
Ensembl chr 1:146,037,426...146,043,097
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MFAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:159,534,202...159,539,750
Ensembl chr 5:159,534,202...159,539,750
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
affects expression |
ISO |
Azacitidine affects the expression of MFGE8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 1:140,845,478...140,860,882
Ensembl chr 1:140,845,465...140,860,894
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of MGMT mRNA Azacitidine results in decreased methylation of MGMT protein |
CTD |
PMID:7511991 PMID:12807730 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9] |
CTD |
PMID:19148494 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Morf4l2 |
mortality factor 4 like 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MORF4L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:107,394,468...107,405,564
Ensembl chr X:107,394,486...107,405,564
|
|
G |
Mov10l1 |
Mov10 like RISC complex RNA helicase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MOV10L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:129,973,391...130,039,306
Ensembl chr 7:129,973,480...130,037,344
|
|
G |
Msrb2 |
methionine sulfoxide reductase B2 |
increases expression |
ISO |
Azacitidine results in increased expression of MSRB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:86,066,841...86,148,131
Ensembl chr17:86,066,833...86,148,130
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Azacitidine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Mtrex |
Mtr4 exosome RNA helicase |
increases expression |
ISO |
Azacitidine results in increased expression of MTREX mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:44,726,716...44,787,013
Ensembl chr 2:44,717,781...44,786,963
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
Azacitidine analog results in decreased expression of MYC mRNA MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myf5 |
myogenic factor 5 |
increases expression |
ISO |
Azacitidine results in increased expression of MYF5 mRNA |
CTD |
PMID:18938140 |
|
NCBI chr 7:49,729,533...49,732,974
Ensembl chr 7:49,729,533...49,732,764
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression |
EXP |
Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein |
CTD |
PMID:17105402 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Myl2 |
myosin light chain 2 |
increases expression |
EXP |
Azacitidine results in increased expression of MYL2 mRNA |
CTD |
PMID:17105402 |
|
NCBI chr12:39,951,863...39,959,065
Ensembl chr12:39,951,987...39,958,239
|
|
G |
Myod1 |
myogenic differentiation 1 |
increases expression |
EXP ISO |
Azacitidine results in increased expression of MYOD1 mRNA |
CTD |
PMID:18037191 PMID:18938140 |
|
NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
Azacitidine results in increased expression of MYOG mRNA |
CTD |
PMID:18938140 |
|
NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of NCAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Nefl |
neurofilament light |
increases expression |
ISO |
Azacitidine results in increased expression of NEFL mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NFATC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of NIBAN1 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr13:68,949,665...69,101,600
Ensembl chr13:68,949,665...69,101,588
|
|
G |
Nkx2-5 |
NK2 homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of NKX2-5 mRNA |
CTD |
PMID:18557828 |
|
NCBI chr10:16,635,989...16,638,758
Ensembl chr10:16,635,989...16,638,764
|
|
G |
Nlgn3 |
neuroligin 3 |
increases expression |
ISO |
Azacitidine results in increased expression of NLGN3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:71,199,390...71,227,460
Ensembl chr X:71,199,491...71,222,732
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
increases expression |
EXP |
Azacitidine results in increased expression of NME2 protein |
CTD |
PMID:17105402 |
|
NCBI chr10:81,648,216...81,653,717
Ensembl chr10:81,648,216...81,653,717
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression |
ISO |
Azacitidine results in increased expression of NMI mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 3:37,458,891...37,480,984
Ensembl chr 3:37,458,890...37,480,984
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:2,340,034...2,356,427
Ensembl chr 4:2,340,148...2,356,068
|
|
G |
Nphp1 |
nephrocystin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:120,316,048...120,370,089
Ensembl chr 3:120,316,047...120,373,500
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Azacitidine results in increased expression of NPPA |
CTD |
PMID:15005238 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Azacitidine results in increased expression of NPPB |
CTD |
PMID:15005238 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[metacept-1 co-treated with Azacitidine] results in increased expression of NR4A1 |
CTD |
PMID:19148494 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,658,225...14,742,478
Ensembl chr11:14,658,225...14,741,563
|
|
G |
Nrn1 |
neuritin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRN1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:27,925,054...28,002,946
Ensembl chr17:27,925,057...27,969,433
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Azacitidine results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Nts |
neurotensin |
decreases expression |
ISO |
Azacitidine results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:111,422,267...111,452,600
Ensembl chr 3:111,422,267...111,452,971
|
|
G |
Nxt2 |
nuclear transport factor 2-like export factor 2 |
increases expression |
ISO |
Azacitidine results in increased expression of NXT2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:113,509,841...113,517,112
Ensembl chr X:113,510,621...113,517,102
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Azacitidine results in increased expression of OCLN mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:29,634,178...29,647,903
Ensembl chr 9:29,634,179...29,647,903
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression decreases methylation |
ISO |
Azacitidine results in decreased expression of OGG1 protein Azacitidine results in decreased methylation of OGG1 promoter |
CTD |
PMID:22064374 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Olr1201 |
olfactory receptor 1201 |
increases expression |
ISO |
Azacitidine results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:40,383,997...40,384,929
Ensembl chr 8:40,383,918...40,384,966
|
|
G |
Oxr1 |
oxidation resistance 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:80,351,774...80,788,094
Ensembl chr 7:80,351,774...80,788,094
|
|
G |
Oxtr |
oxytocin receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of OXTR mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 4:144,399,326...144,417,598
Ensembl chr 4:144,403,358...144,416,116
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
EXP ISO |
Azacitidine results in increased expression of P4HB protein Azacitidine results in increased expression of P4HB mRNA |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
|
|
G |
Paep |
progestagen associated endometrial protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:2,935,396...2,938,883
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PAK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:162,768,156...162,883,356
Ensembl chr 1:162,768,156...162,883,355
|
|
G |
Pank3 |
pantothenate kinase 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PANK3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:20,591,432...20,615,258
Ensembl chr10:20,591,432...20,615,258
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Azacitidine results in increased cleavage of PARP1 protein Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein] |
CTD |
PMID:32278510 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pax4 |
paired box 4 |
increases expression |
ISO |
Azacitidine results in increased expression of PAX4 mRNA |
CTD |
PMID:18949370 |
|
NCBI chr 4:55,735,640...55,753,461
Ensembl chr 4:55,735,682...55,740,627
|
|
G |
Pcdh10 |
protocadherin 10 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA12 promoter |
CTD |
PMID:18204046 |
|
NCBI chr 2:136,992,355...137,017,705
Ensembl chr 2:136,993,208...137,014,492
|
|
G |
Pcdh18 |
protocadherin 18 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:138,819,957...138,833,932
Ensembl chr 2:138,819,960...138,833,933
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA1 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,951,094...30,215,896
|
|
G |
Pcdha10 |
protocadherin alpha 10 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA10 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:30,010,918...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdha11 |
protocadherin alpha 11 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA11 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:30,017,918...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdha2 |
protocadherin alpha 2 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA2 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,960,072...30,215,896
|
|
G |
Pcdha3 |
protocadherin alpha 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA3 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,966,245...30,215,896
|
|
G |
Pcdha4 |
protocadherin alpha 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA4 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,950,217...30,215,901
Ensembl chr18:29,987,206...30,215,897 Ensembl chr18:29,987,206...30,215,897 Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdha5 |
protocadherin alpha 5 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA5 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,980,268...30,215,897
|
|
G |
Pcdha6 |
protocadherin alpha 6 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA6 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,987,206...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdha7 |
protocadherin alpha 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA7 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:29,993,361...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdha9 |
protocadherin alpha 9 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA8 promoter; Azacitidine affects the methylation of PCDHA9 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:30,004,565...30,215,897
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pcdhb20 |
protocadherin beta 20 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:30,581,530...30,584,905
Ensembl chr18:30,581,530...30,584,905
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:30,398,113...30,400,695
Ensembl chr18:30,398,113...30,400,695
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression multiple interactions |
EXP |
Azacitidine results in decreased expression of PCNA protein [Cisplatin co-treated with Azacitidine] results in decreased expression of PCNA protein |
CTD |
PMID:19723570 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of PDK4 protein Azacitidine results in decreased methylation of PDK4 promoter |
CTD |
PMID:28003426 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PECAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr10:94,850,971...94,913,202
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PFN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:57,273,003...57,275,708
Ensembl chr10:57,273,005...57,275,708
|
|
G |
Phactr2 |
phosphatase and actin regulator 2 |
increases expression |
ISO |
Azacitidine results in increased expression of PHACTR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:7,352,050...7,633,991
Ensembl chr 1:7,355,154...7,480,825
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of PIP5K1A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:196,227,669...196,270,949
Ensembl chr 2:196,227,670...196,270,826
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:95,429,879...95,697,734
|
|
G |
Pitx3 |
paired-like homeodomain 3 |
increases expression |
EXP |
Azacitidine results in increased expression of PITX3 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 1:265,886,766...265,899,947
Ensembl chr 1:265,887,230...265,899,958
|
|
G |
Pja1 |
praja ring finger ubiquitin ligase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PJA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:69,213,645...69,218,601
Ensembl chr X:69,213,645...69,218,556
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
increases expression |
ISO |
Azacitidine results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:263,922,201...263,959,318
Ensembl chr 1:263,922,201...263,959,318
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
ISO |
Azacitidine results in increased expression of PKM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Plcb1 |
phospholipase C beta 1 |
decreases methylation decreases response to substance increases response to substance increases expression |
ISO |
Azacitidine results in decreased methylation of PLCB1 promoter PLCB1 promoter modified form results in decreased susceptibility to Azacitidine PLCB1 mRNA results in increased susceptibility to Azacitidine; PLCB1 protein results in increased susceptibility to Azacitidine Azacitidine results in increased expression of PLCB1 mRNA; Azacitidine results in increased expression of PLCB1 protein |
CTD |
PMID:19805378 |
|
NCBI chr 3:127,721,244...128,419,565
Ensembl chr 3:128,155,069...128,419,545
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PLPP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:44,664,076...44,726,820
Ensembl chr 2:44,664,124...44,726,689
|
|
G |
Pls3 |
plastin 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:119,030,311...119,124,268
Ensembl chr X:119,030,419...119,124,250
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression |
ISO |
Azacitidine results in increased expression of PML mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of PPARG promoter Azacitidine results in increased expression of PPARG mRNA |
CTD |
PMID:19589179 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions increases expression decreases methylation |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] Azacitidine results in increased expression of PPP2CA mRNA Azacitidine results in decreased methylation of PPP2CA promoter |
CTD |
PMID:19155497 |
|
NCBI chr10:37,534,449...37,554,861
Ensembl chr10:37,535,871...37,554,664
|
|
G |
Prdx4 |
peroxiredoxin 4 |
decreases expression |
EXP |
Azacitidine results in decreased expression of PRDX4 protein |
CTD |
PMID:17105402 |
|
NCBI chr X:43,495,453...43,512,994
Ensembl chr X:43,497,763...43,512,991
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein |
CTD |
PMID:20823114 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prom1 |
prominin 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PROM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
|
|
G |
Prss12 |
serine protease 12 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884
|
|
G |
Psen1 |
presenilin 1 |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of PSEN1 promoter Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter] |
CTD |
PMID:22841775 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of PTHLH mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:181,663,425...181,674,181
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
increases expression |
ISO |
Azacitidine results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,982,122...9,012,585
Ensembl chr 3:8,982,122...9,012,585
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
increases expression |
ISO |
Azacitidine results in increased expression of PTPRC mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:55,061,561...55,174,150
Ensembl chr13:55,061,562...55,173,692
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
increases expression |
EXP |
Azacitidine results in increased expression of PTPRO mRNA |
CTD |
PMID:14508512 |
|
NCBI chr 4:171,250,766...171,461,571
Ensembl chr 4:171,250,818...171,461,677
|
|
G |
Rab13 |
RAB13, member RAS oncogene family |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of RAB13 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 2:189,581,209...189,586,358
Ensembl chr 2:189,581,644...189,586,338
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
increases expression |
ISO |
Azacitidine results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:220,483,529...220,491,469
Ensembl chr 1:220,480,834...220,491,469
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RACGAP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:141,277,303...141,308,849
Ensembl chr 7:141,277,312...141,307,233
|
|
G |
Ranbp2 |
RAN binding protein 2 |
increases expression |
ISO |
Azacitidine results in increased expression of RANBP2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:28,027,054...28,076,664 NCBI chr20:28,365,538...28,375,676
Ensembl chr20:28,027,054...28,076,664 Ensembl chr20:28,027,054...28,076,664
|
|
G |
Rasa3 |
RAS p21 protein activator 3 |
increases expression |
ISO |
Azacitidine results in increased expression of RASA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:81,320,090...81,434,239
Ensembl chr16:81,318,633...81,434,363
|
|
G |
Rcn1 |
reticulocalbin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of RCN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:95,404,863...95,419,110
Ensembl chr 3:95,406,284...95,418,679
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Azacitidine affects the localization of RELA protein |
CTD |
PMID:18443271 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Azacitidine results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Rfc3 |
replication factor C subunit 3 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr12:1,460,581...1,471,344
Ensembl chr12:1,460,538...1,471,357
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[trichostatin A co-treated with Azacitidine] results in increased expression of RHOB protein; Azacitidine promotes the reaction [trichostatin A results in increased expression of RHOB mRNA] |
CTD |
PMID:18047684 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:220,335,036...220,342,319
Ensembl chr 1:220,335,254...220,342,297
|
|
G |
Rpp21 |
ribonuclease P/MRP subunit p21 |
increases expression |
ISO |
Azacitidine results in increased expression of RPP21 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:2,515,541...2,517,471
Ensembl chr20:2,515,520...2,517,498
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Azacitidine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:21245298 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rpsa |
ribosomal protein SA |
decreases expression |
ISO |
Azacitidine results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:128,806,053...128,809,987
Ensembl chr 8:128,806,129...128,809,986
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Azacitidine results in increased expression of RRM2B mRNA |
CTD |
PMID:19010910 |
|
NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein |
CTD |
PMID:18829986 |
|
NCBI chr20:4,127,644...4,132,616
Ensembl chr20:4,127,644...4,132,616
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr11:32,765,147...33,003,061
Ensembl chr11:32,769,165...33,003,021
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of RUNX3 gene |
CTD |
PMID:18058463 |
|
NCBI chr 5:153,507,093...153,531,137
Ensembl chr 5:153,507,093...153,531,137
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
decreases expression |
ISO |
Azacitidine results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:189,913,433...189,919,947
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Azacitidine results in increased expression of S100A9 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Sall4 |
spalt-like transcription factor 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of SALL4 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:165,520,155...165,538,176
Ensembl chr 3:165,520,392...165,537,940
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:11,969,720...11,982,141
Ensembl chr 7:11,969,720...11,982,141
|
|
G |
Sdcbp |
syndecan binding protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,471,664...19,498,499
Ensembl chr 5:19,471,664...19,498,485
|
|
G |
Sema3a |
semaphorin 3A |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
|
|
G |
Sema6c |
semaphorin 6C |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA6C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:196,330,777...196,347,218
Ensembl chr 2:196,334,626...196,344,008
|
|
G |
Senp3 |
SUMO specific peptidase 3 |
increases expression |
ISO |
Azacitidine results in increased expression of SENP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:56,277,609...56,286,867
Ensembl chr10:56,277,615...56,286,391
|
|
G |
Slbp |
stem-loop binding protein |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [sodium arsenite results in decreased expression of SLBP mRNA] |
CTD |
PMID:25266719 |
|
NCBI chr14:82,356,916...82,366,368
Ensembl chr14:82,356,916...82,366,368
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
increases response to substance multiple interactions increases uptake |
ISO |
SLC28A1 protein results in increased susceptibility to Azacitidine [SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Azacitidine] |
CTD |
PMID:19139132 |
|
NCBI chr 1:142,948,942...142,992,410
Ensembl chr 1:142,950,540...142,992,615
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SLC29A2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:220,306,622...220,314,631
Ensembl chr 1:220,400,855...220,407,189 Ensembl chr 1:220,400,855...220,407,189
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Butyrates] affects the expression of SLC5A5 mRNA Azacitidine results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16954431 PMID:17164311 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Snu13 |
small nuclear ribonucleoprotein 13 |
increases expression |
ISO |
Azacitidine results in increased expression of SNU13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:123,282,754...123,287,721
Ensembl chr 7:123,282,754...123,287,721
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
affects expression |
ISO |
Azacitidine affects the expression of SOCS3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sox13 |
SRY-box transcription factor 13 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:50,434,702...50,479,118
Ensembl chr13:50,434,702...50,479,657
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
EXP |
Azacitidine results in increased expression of SOX2 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:14,932,348...14,937,336
Ensembl chr10:14,932,348...14,937,336
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects expression |
ISO |
Azacitidine affects the expression of SOX9 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [SP1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [SP1 protein binds to KIR2DL4 promoter] Azacitidine results in decreased expression of SP1 mRNA Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 PMID:18945643 PMID:20823114 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Azacitidine results in increased expression of SP7 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 7:143,957,316...143,967,488
Ensembl chr 7:143,958,858...143,967,484
|
|
G |
Spag5 |
sperm associated antigen 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr10:65,552,780...65,585,773
Ensembl chr10:65,566,171...65,585,760 Ensembl chr10:65,566,171...65,585,760
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRPX mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:14,146,618...14,220,756
Ensembl chr X:14,150,038...14,220,662
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:2,879,312...2,886,505
Ensembl chr 6:2,880,518...2,886,465
|
|
G |
Ssx2ip |
SSX family member 2 interacting protein |
increases expression |
ISO |
Azacitidine results in increased expression of SSX2IP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:252,263,323...252,296,049
Ensembl chr 2:252,263,386...252,296,051
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of ST3GAL6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr11:44,176,518...44,237,119
Ensembl chr11:44,192,940...44,237,100
|
|
G |
St8sia2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ST8SIA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:135,336,374...135,406,699
Ensembl chr 1:135,336,374...135,406,700
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STC2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:16,542,909...16,552,675
Ensembl chr10:16,542,882...16,553,295
|
|
G |
Stk38 |
serine/threonine kinase 38 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:6,224,300...6,257,613
Ensembl chr20:6,224,296...6,257,604
|
|
G |
Sulf1 |
sulfatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:5,999,520...6,186,901
Ensembl chr 5:5,999,475...6,186,329
|
|
G |
Sult1c2a |
sulfotransferase family, cytosolic, 1C, member 2a |
increases expression |
ISO |
Azacitidine results in increased expression of SULT1C2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 9:4,152,588...4,168,355
Ensembl chr 9:4,152,589...4,168,221
|
|
G |
Tat |
tyrosine aminotransferase |
increases expression |
ISO |
Azacitidine results in increased expression of TAT mRNA |
CTD |
PMID:27590069 |
|
NCBI chr19:41,675,639...41,686,195
Ensembl chr19:41,675,355...41,686,229
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TBC1D4 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:85,927,978...86,105,829
Ensembl chr15:85,930,044...86,105,273
|
|
G |
Tcea1 |
transcription elongation factor A1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:14,511,183...14,548,494
Ensembl chr 5:14,511,183...14,548,429
|
|
G |
Tecpr2 |
tectonin beta-propeller repeat containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TECPR2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:135,304,536...135,405,865
Ensembl chr 6:135,313,008...135,402,814
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases expression |
EXP |
Azacitidine results in increased expression of TEK mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression multiple interactions decreases methylation decreases activity |
ISO |
Azacitidine analog results in decreased expression of TERT mRNA; Azacitidine results in decreased expression of TERT mRNA E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]; MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] Azacitidine results in decreased methylation of TERT promoter |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TFE3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:15,574,579...15,587,826
Ensembl chr X:15,575,934...15,587,419
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]; Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18493985 PMID:22841775 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Thumpd1 |
THUMP domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of THUMPD1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:189,457,582...190,370,515
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tjp1 |
tight junction protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TJP1 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TMED3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:97,075,194...97,083,107
Ensembl chr 8:97,075,160...97,083,120
|
|
G |
Tmpo |
thymopoietin |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 7:31,847,412...31,872,416
Ensembl chr 7:31,847,410...31,872,423
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
Azacitidine results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases response to substance |
EXP ISO |
Azacitidine results in increased expression of TNF mRNA Azacitidine results in increased susceptibility to TNF protein |
CTD |
PMID:17156202 PMID:18829727 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18829727 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tnni3 |
troponin I3, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNI3 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNT2 protein |
CTD |
PMID:22496879 |
|
NCBI chr13:52,662,974...52,680,992
Ensembl chr13:52,662,996...52,680,990
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA; [Curcumin co-treated with Azacitidine] results in decreased expression of TOP2A mRNA |
CTD |
PMID:18348204 PMID:18720364 |
|
NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:171,355,876...171,415,354
Ensembl chr 5:171,355,876...171,415,354
|
|
G |
Tpd52 |
tumor protein D52 |
increases expression |
EXP |
Azacitidine results in increased expression of TPD52 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:94,959,732...95,041,277
Ensembl chr 2:95,008,311...95,040,514
|
|
G |
Tpm2 |
tropomyosin 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TPM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:59,016,616...59,025,971
Ensembl chr 5:59,016,622...59,025,631
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
Azacitidine results in increased expression of TPO mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
|
|
G |
Tpsg1 |
tryptase gamma 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,724,531...14,731,259
Ensembl chr10:14,727,180...14,731,086
|
|
G |
Trh |
thyrotropin releasing hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRH mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:124,110,716...124,113,242
Ensembl chr 4:124,110,716...124,113,242
|
|
G |
Trib1 |
tribbles pseudokinase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRIB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:99,954,492...99,961,026
Ensembl chr 7:99,954,492...99,961,026
|
|
G |
Trim8 |
tripartite motif-containing 8 |
increases expression |
ISO |
Azacitidine results in increased expression of TRIM8 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:266,255,797...266,270,694
Ensembl chr 1:266,255,797...266,270,694
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
[Azacitidine affects the methylation of TSC1 promoter] which affects the expression of TSC1 mRNA |
CTD |
PMID:18538015 |
|
NCBI chr 3:7,219,955...7,269,063
Ensembl chr 3:7,237,192...7,265,145
|
|
G |
Tsc2 |
TSC complex subunit 2 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of TSC2 promoter [Azacitidine affects the methylation of TSC2 promoter] which affects the expression of TSC2 mRNA Azacitidine results in increased expression of TSC2 mRNA |
CTD |
PMID:18538015 PMID:19250671 |
|
NCBI chr10:13,962,006...13,996,684
Ensembl chr10:13,961,947...13,996,584
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
Azacitidine results in increased expression of TSHR mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:115,170,290...115,306,871
Ensembl chr 6:115,170,865...115,306,871
|
|
G |
Tspan32 |
tetraspanin 32 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TSPAN32 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:216,189,535...216,206,202
Ensembl chr 1:216,191,886...216,206,200
|
|
G |
Ttk |
Ttk protein kinase |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 8:91,368,065...91,405,995
Ensembl chr 8:91,368,111...91,405,993
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:161,236,971...161,239,371
Ensembl chr 3:161,236,898...161,241,159
|
|
G |
Uhmk1 |
U2AF homology motif kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of UHMK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:88,521,625...88,536,728
Ensembl chr13:88,521,625...88,536,728
|
|
G |
Ush2a |
usherin |
increases expression |
ISO |
Azacitidine results in increased expression of USH2A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:106,750,738...107,434,195
Ensembl chr13:106,751,625...107,427,329
|
|
G |
Ushbp1 |
USH1 protein network component harmonin binding protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of USHBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:19,781,276...19,791,832
Ensembl chr16:19,781,279...19,791,832
|
|
G |
Vim |
vimentin |
decreases expression increases expression multiple interactions |
EXP ISO |
Azacitidine results in decreased expression of VIM protein Azacitidine results in increased expression of VIM mRNA; Azacitidine results in increased expression of VIM protein [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wdr47 |
WD repeat domain 47 |
decreases expression |
ISO |
Azacitidine results in decreased expression of WDR47 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:211,380,894...211,441,817
Ensembl chr 2:211,381,036...211,441,815
|
|
G |
Wnt10b |
Wnt family member 10B |
increases expression |
EXP |
Azacitidine results in increased expression of WNT10B mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 7:140,448,284...140,466,159
Ensembl chr 7:140,448,465...140,454,268
|
|
G |
Wnt5a |
Wnt family member 5A |
increases expression |
ISO |
Azacitidine results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
increases expression |
ISO |
Azacitidine results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:147,577,149...147,693,033
Ensembl chr 2:147,577,089...147,693,082
|
|
G |
Xaf1 |
XIAP associated factor 1 |
decreases expression decreases methylation increases expression |
ISO |
Azacitidine results in decreased expression of XAF1 mRNA alternative form Azacitidine results in decreased methylation of XAF1 promoter Azacitidine results in increased expression of XAF1 mRNA; Azacitidine results in increased expression of XAF1 protein |
CTD |
PMID:19077051 PMID:19549372 |
|
NCBI chr10:58,860,647...58,872,782
Ensembl chr10:58,860,940...58,873,674
|
|
G |
Zfp189 |
zinc finger protein 189 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ZNF189 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:64,789,432...64,801,079
Ensembl chr 5:64,789,456...64,800,810
|
|
G |
Zfp64 |
zinc finger protein 64 |
affects methylation |
ISO |
Azacitidine affects the methylation of ZFP64 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:165,713,070...165,741,932
Ensembl chr 3:165,713,020...165,741,967
|
|
G |
Zp3 |
zona pellucida glycoprotein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of ZP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:23,735,225...23,752,734
Ensembl chr12:23,735,223...23,742,190
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
affects binding |
ISO |
acetoacetyl CoA binds to HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
|
|
|
G |
Acly |
ATP citrate lyase |
increases abundance |
ISO |
ACLY protein results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:28077572 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
App |
amyloid beta precursor protein |
affects localization increases secretion multiple interactions |
ISO |
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases activity |
EXP |
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein |
CTD |
PMID:8075222 |
|
NCBI chr 3:8,967,984...8,981,959
Ensembl chr 3:8,968,417...8,981,362
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:25440059 |
|
NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Acetyl Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:4,440,982...4,492,949
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:30213948 |
|
NCBI chr10:110,893,261...110,907,256
Ensembl chr10:110,893,232...110,907,243
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions affects binding |
ISO |
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein |
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:53,446,185...53,526,727
Ensembl chr 9:53,446,194...53,526,728
|
|
|
G |
Ada |
adenosine deaminase |
decreases metabolic processing increases metabolic processing |
ISO |
ADA alternative form results in decreased metabolism of Adenosine ADA protein results in increased metabolism of Adenosine |
CTD |
PMID:16221767 |
|
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions affects binding |
ISO EXP |
Adenosine analog binds to and affects the activity of ADORA1 protein; Adenosine analog binds to and results in decreased activity of ADORA1 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein] [lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine; Adenosine analog binds to and results in increased activity of ADORA1 protein Adenosine binds to ADORA1 protein |
CTD |
PMID:10649980 PMID:11520205 PMID:18404447 PMID:20571079 PMID:20932874 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions affects binding |
ISO |
Adenosine analog binds to and results in decreased activity of ADORA2A protein; Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA] Adenosine binds to ADORA2A protein |
CTD |
PMID:18404447 PMID:20067761 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Adora2b |
adenosine A2B receptor |
affects response to substance |
ISO |
ADORA2B protein affects the susceptibility to Adenosine |
CTD |
PMID:16920807 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions increases expression affects binding |
ISO |
Adenosine analog binds to and affects the activity of ADORA3 protein; Adenosine analog binds to and results in decreased activity of ADORA3 protein; Adenosine analog binds to and results in increased activity of ADORA3 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein] Adenosine results in increased expression of ADORA3 mRNA Adenosine binds to ADORA3 protein |
CTD |
PMID:11520205 PMID:18404447 PMID:20067761 PMID:20571079 |
|
NCBI chr 2:208,336,909...208,379,217
Ensembl chr 2:208,373,154...208,376,803
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Adenosine inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 9:94,197,616...94,201,910
Ensembl chr 9:94,197,618...94,201,084
|
|
G |
Ampd2 |
adenosine monophosphate deaminase 2 |
multiple interactions |
ISO |
[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine |
CTD |
PMID:25496463 |
|
NCBI chr 2:210,861,624...210,874,348
Ensembl chr 2:210,861,625...210,874,304
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases localization multiple interactions |
ISO |
Adenosine results in increased localization of BAX protein Thymidine inhibits the reaction [Adenosine results in increased localization of BAX protein] |
CTD |
PMID:11570579 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of BCL2L1 mRNA; Adenosine results in decreased expression of BCL2L1 protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:20063052 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC2 mRNA; Adenosine results in decreased expression of BIRC2 protein |
CTD |
PMID:20063052 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC3 mRNA |
CTD |
PMID:20063052 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Thymidine inhibits the reaction [Adenosine results in increased activity of CASP3 protein] |
CTD |
PMID:11570579 PMID:16469385 PMID:17303086 PMID:20063052 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO EXP |
Adenosine results in increased activity of CASP8 protein Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein] |
CTD |
PMID:16469385 PMID:17303086 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Adenosine results in increased activity of CASP9 protein Thymidine inhibits the reaction [Adenosine results in increased activity of CASP9 protein] |
CTD |
PMID:11570579 PMID:16469385 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Adenosine results in increased expression of CD14 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of CFLAR mRNA; Adenosine results in decreased expression of CFLAR mRNA alternative form; Adenosine results in decreased expression of CFLAR protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein] |
CTD |
PMID:17303086 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity multiple interactions |
ISO |
Adenosine results in increased activity of CFTR protein [Isoproterenol co-treated with Adenosine] results in increased activity of CFTR protein |
CTD |
PMID:15039139 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of DIABLO mRNA; Adenosine results in increased expression of DIABLO protein Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein] |
CTD |
PMID:20063052 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of DPP4 mRNA; Adenosine results in decreased expression of DPP4 protein [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Adenosine results in increased expression of ESR1 protein |
CTD |
PMID:29360751 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
ISO |
Adenosine results in increased expression of ESR2 protein |
CTD |
PMID:29360751 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of FADD mRNA Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA] |
CTD |
PMID:17303086 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of FASLG protein [Adenosine co-treated with Coformycin] results in decreased expression of FASL mRNA |
CTD |
PMID:11992407 PMID:16419169 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
ISO |
Adenosine results in increased expression of FSHB protein |
CTD |
PMID:29360751 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of GZMB mRNA |
CTD |
PMID:11992407 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Adenosine results in increased expression of HIF1A mRNA |
CTD |
PMID:20067761 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Adenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of IFNG protein |
CTD |
PMID:11992407 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Adenosine promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Adenosine results in increased expression of IL10 mRNA; Adenosine results in increased expression of IL10 protein |
CTD |
PMID:11023991 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of IL12B protein Adenosine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:11023991 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1] |
CTD |
PMID:24878381 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of IL2 protein |
CTD |
PMID:11992407 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Ly96 |
lymphocyte antigen 96 |
increases expression |
ISO |
Adenosine results in increased expression of LY96 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr 5:1,972,212...1,989,448
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Adenosine results in decreased phosphorylation of MAPK3 protein [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of MYC protein Thymidine inhibits the reaction [Adenosine results in decreased expression of MYC protein]; Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein] |
CTD |
PMID:9808420 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA |
CTD |
PMID:24224954 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases stability multiple interactions |
EXP |
Adenosine results in decreased stability of NOS2 mRNA Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[alpha,beta-methyleneadenosine 5'-diphosphate results in decreased activity of NT5E protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine] |
CTD |
PMID:23437309 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Adenosine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of PRF1 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
[Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine |
CTD |
PMID:11562489 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:24224954 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
decreases secretion |
EXP |
Adenosine results in decreased secretion of REN protein |
CTD |
PMID:3044993 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein |
CTD |
PMID:24224954 |
|
NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
affects transport multiple interactions |
ISO |
SLC28A1 protein affects the transport of Adenosine Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9124315 |
|
NCBI chr 1:142,948,942...142,992,410
Ensembl chr 1:142,950,540...142,992,615
|
|
G |
Slc28a2 |
solute carrier family 28 member 2 |
increases transport |
ISO |
SLC28A2 protein results in increased transport of Adenosine |
CTD |
PMID:10087507 |
|
NCBI chr 3:114,355,003...114,647,382
Ensembl chr 3:114,355,798...114,647,382
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions increases uptake affects abundance |
ISO EXP |
4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; [4-nitrobenzylthioinosine results in decreased activity of SLC29A1 protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]; [SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine; Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] SLC29A1 protein alternative form results in increased uptake of Adenosine; SLC29A1 protein results in increased uptake of Adenosine cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; draflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine] Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] SLC29A1 affects the abundance of Adenosine |
CTD |
PMID:9353301 PMID:9396714 PMID:11179696 PMID:21283641 PMID:21872611 PMID:23437309 PMID:28041785 |
|
NCBI chr 9:17,784,468...17,799,008
Ensembl chr 9:17,784,468...17,799,005
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
increases uptake |
ISO |
SLC29A2 protein results in increased uptake of Adenosine |
CTD |
PMID:9396714 |
|
NCBI chr 1:220,306,622...220,314,631
Ensembl chr 1:220,400,855...220,407,189 Ensembl chr 1:220,400,855...220,407,189
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Adenosine |
CTD |
PMID:19164483 |
|
NCBI chr20:30,289,527...30,327,343
Ensembl chr20:30,287,424...30,327,361
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
EXP |
Adenosine results in increased expression of SLC5A5 mRNA; Adenosine results in increased expression of SLC5A5 protein |
CTD |
PMID:16954431 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression affects localization multiple interactions |
ISO |
Adenosine results in increased expression of TLR4 mRNA Adenosine affects the localization of TLR4 protein Adenosine promotes the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of TLR4 protein] |
CTD |
PMID:21538184 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO |
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; [Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] Adenosine results in decreased expression of TNF protein |
CTD |
PMID:11023991 PMID:21538184 PMID:24224954 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein |
CTD |
PMID:24224954 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases metabolic processing |
ISO |
UPP1 protein results in increased metabolism of Adenosine |
CTD |
PMID:15772079 |
|
NCBI chr14:89,314,234...89,334,060
Ensembl chr14:89,314,176...89,334,276
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression increases secretion |
ISO |
Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] Adenosine results in increased expression of VEGFA mRNA Adenosine results in increased secretion of VEGFA protein |
CTD |
PMID:20067761 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
EXP |
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein] |
CTD |
PMID:21130751 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein] |
CTD |
PMID:23959441 |
|
NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
affects binding multiple interactions |
ISO |
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]] |
CTD |
PMID:24059442 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:17,171,510...17,215,108
Ensembl chr X:17,540,458...17,540,952 Ensembl chr X:17,540,458...17,540,952
|
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein |
CTD |
PMID:15944274 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein |
CTD |
PMID:15944274 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein |
CTD |
PMID:15944274 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
LOC102552569 |
P2Y purinoceptor 11-like |
multiple interactions |
ISO |
[adenosine 5'-O-(3-thiotriphosphate) binds to and results in increased activity of P2RY11 protein] which results in increased expression of CXCL8 protein; adenosine 5'-O-(3-thiotriphosphate) binds to and results in increased activity of P2RY11 protein |
CTD |
PMID:19815812 |
|
NCBI chr 8:21,910,636...21,911,499
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
affects response to substance |
ISO |
P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate) |
CTD |
PMID:12873706 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein] |
CTD |
PMID:11140687 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein |
CTD |
PMID:10609638 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases abundance |
ISO |
ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate |
CTD |
PMID:25440059 |
|
NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:17,171,510...17,215,108
Ensembl chr X:17,540,458...17,540,952 Ensembl chr X:17,540,458...17,540,952
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Adenosine Monophosphate results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Tp73 |
tumor protein p73 |
affects abundance |
ISO |
TP73 protein affects the abundance of Adenosine Monophosphate |
CTD |
PMID:25554796 |
|
NCBI chr 5:171,355,876...171,415,354
Ensembl chr 5:171,355,876...171,415,354
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects binding |
ISO |
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form |
CTD |
PMID:18336795 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ak1 |
adenylate kinase 1 |
increases abundance |
ISO |
AK1 protein results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:11390963 |
|
NCBI chr 3:11,652,143...11,659,135
|
|
G |
Alb |
albumin |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein] |
CTD |
PMID:17303692 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cd40lg |
CD40 ligand |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] |
CTD |
PMID:11297035 PMID:17043144 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] |
CTD |
PMID:15684079 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] |
CTD |
PMID:16772608 PMID:18004210 PMID:18394438 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate] |
CTD |
PMID:21128666 |
|
NCBI chr 9:100,921,565...100,930,399
Ensembl chr 9:100,921,565...100,930,399
|
|
G |
Epha4 |
Eph receptor A4 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr 9:83,111,222...83,253,486
Ensembl chr 9:83,111,222...83,253,458
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions decreases activity |
ISO |
Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein] Adenosine Diphosphate results in decreased activity of ERN1 protein |
CTD |
PMID:25164867 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
F2 |
coagulation factor II |
increases abundance multiple interactions |
ISO |
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:15342215 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions increases secretion |
ISO |
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgb |
fibrinogen beta chain |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Fgg |
fibrinogen gamma chain |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gas6 |
growth arrest specific 6 |
increases response to substance |
ISO |
GAS6 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of HRAS protein |
CTD |
PMID:16388579 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24849676 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate] |
CTD |
PMID:16214444 |
|
NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:90,397,960...90,416,550
Ensembl chr10:90,398,132...90,415,070
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:71,342,770...71,347,623
Ensembl chr X:71,342,775...71,347,619
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:92,667,869...92,783,413
Ensembl chr10:92,667,869...92,783,410
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:15034929 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:15034929 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24466103 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24466103 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
increases response to substance |
ISO |
MERTK protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:121,235,230...121,340,932
Ensembl chr 3:121,235,119...121,342,444
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate] |
CTD |
PMID:11498454 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases activity |
ISO |
Adenosine Diphosphate analog results in decreased activity of NT5E protein |
CTD |
PMID:18404487 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein] |
CTD |
PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 |
|
NCBI chr 2:149,440,807...149,482,592
Ensembl chr 2:149,441,598...149,444,548
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pf4 |
platelet factor 4 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PF4 protein |
CTD |
PMID:19428933 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:139,702,066...139,722,132
Ensembl chr 7:139,685,573...139,722,132
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Adenosine Diphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,836,105...13,838,731
Ensembl chr10:13,836,128...13,838,765
|
|
G |
Ppbp |
pro-platelet basic protein |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PPBP protein |
CTD |
PMID:19428933 |
|
NCBI chr14:18,852,433...18,853,237
Ensembl chr14:18,851,954...18,853,315
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of PPP5C protein |
CTD |
PMID:23184943 |
|
NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases glutathionylation multiple interactions |
EXP |
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:164,665,462...164,711,936
Ensembl chr 3:164,665,532...164,711,848
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein] |
CTD |
PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Sirt3 |
sirtuin 3 |
decreases abundance |
ISO |
SIRT3 protein results in decreased abundance of Adenosine Diphosphate |
CTD |
PMID:23166782 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:214,375,555...214,385,886
Ensembl chr 1:214,375,515...214,385,885
|
|
G |
Thbs1 |
thrombospondin 1 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of THBS1 protein |
CTD |
PMID:17303692 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase |
increases response to substance |
ISO |
TYRO3 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:111,597,102...111,616,142
Ensembl chr 3:111,597,102...111,616,142
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of VASP protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein] |
CTD |
PMID:25329809 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
increases hydrolysis |
ISO |
ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite |
CTD |
PMID:21498885 |
|
NCBI chr11:64,861,772...64,868,112
Ensembl chr11:64,861,768...64,868,108
|
|
G |
Adprs |
ADP-ribosylserine hydrolase |
increases hydrolysis multiple interactions |
ISO |
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose] |
CTD |
PMID:21498885 |
|
NCBI chr 5:144,336,312...144,341,586
Ensembl chr 5:144,336,312...144,341,586
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose] |
CTD |
PMID:10318960 |
|
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions increases activity |
EXP ISO |
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium] |
CTD |
PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 |
|
NCBI chr20:11,434,062...11,482,880
Ensembl chr20:11,436,267...11,482,051
|
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions increases expression |
ISO |
[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]] Ribose results in increased expression of AGER protein |
CTD |
PMID:30101366 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
B2m |
beta-2 microglobulin |
increases glycation |
ISO |
Ribose results in increased glycation of B2M protein |
CTD |
PMID:21864514 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein |
CTD |
PMID:21220914 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases phosphorylation |
ISO |
Ribose results in increased phosphorylation of CHUK protein |
CTD |
PMID:30101366 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases phosphorylation |
ISO |
Ribose results in increased phosphorylation of IKBKB protein |
CTD |
PMID:30101366 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
ISO |
[Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein Ribose results in increased phosphorylation of NFKBIA protein |
CTD |
PMID:30101366 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions |
ISO |
Ribose results in increased phosphorylation of RELA protein [Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein] |
CTD |
PMID:30101366 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects activity |
ISO |
Adenylyl Imidodiphosphate affects the activity of CFTR protein |
CTD |
PMID:15657297 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,195,606...19,196,508
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases hydrolysis |
ISO EXP |
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 PMID:23685082 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects activity increases hydrolysis affects binding |
ISO |
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein |
CTD |
PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15737336 PMID:15838832 PMID:16156793 PMID:18336795 PMID:18955043 PMID:32472168 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects activity affects metabolic processing |
EXP ISO |
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine] |
CTD |
PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 PMID:32003934 PMID:32472168 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions affects activity increases hydrolysis |
ISO |
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:14978246 PMID:16156793 PMID:32472168 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects binding |
ISO |
Adenosine Triphosphate binds to ABCC6 protein |
CTD |
PMID:11880368 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
EXP |
Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]] |
CTD |
PMID:19095654 |
|
NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
EXP ISO |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases hydrolysis multiple interactions |
ISO |
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate] |
CTD |
PMID:18829547 PMID:32003934 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases secretion |
EXP |
ADCYAP1 protein results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:18563302 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions decreases expression |
EXP |
Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases activity multiple interactions |
ISO |
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
increases abundance |
ISO |
ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29031482 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Alk |
ALK receptor tyrosine kinase |
affects binding multiple interactions |
ISO |
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate] |
CTD |
PMID:22072639 |
|
NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases response to substance multiple interactions |
ISO |
ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:27466191 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
EXP |
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein] |
CTD |
PMID:20655937 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] |
CTD |
PMID:22906069 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr10:68,247,800...69,347,223
Ensembl chr10:68,248,655...68,517,564
|
|
G |
Asic3 |
acid sensing ion channel subunit 3 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 4:7,287,868...7,293,295
Ensembl chr 4:7,288,855...7,292,901
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein |
CTD |
PMID:20964302 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions increases phosphorylation |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein |
CTD |
PMID:19405516 PMID:20964302 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases hydrolysis |
EXP |
ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:11584374 |
|
NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases secretion |
EXP |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein |
CTD |
PMID:21503959 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
multiple interactions |
ISO |
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
multiple interactions |
EXP |
CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr20:13,836,032...13,963,003
Ensembl chr20:13,836,030...13,963,003
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] |
CTD |
PMID:12044622 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein] |
CTD |
PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 PMID:25288807 PMID:25448682 PMID:26431797 PMID:26586371 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of CASP3 Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3] |
CTD |
PMID:19448140 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:24149798 PMID:25288807 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of CAT mRNA |
CTD |
PMID:22129738 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein] |
CTD |
PMID:26522449 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:14975680 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr 3:147,713,808...147,760,375
Ensembl chr 3:147,713,821...147,757,862
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr20:5,108,692...5,113,675
Ensembl chr20:5,106,890...5,113,112
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:25288807 |
|
NCBI chr20:10,966,357...10,968,399
Ensembl chr20:10,966,331...10,968,432
|
|
G |
Ctsb |
cathepsin B |
increases activity multiple interactions |
ISO |
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein] |
CTD |
PMID:26522449 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein] |
CTD |
PMID:26522449 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Dmd |
dystrophin |
increases secretion multiple interactions |
ISO |
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:24349043 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26104857 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
EXP |
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA] |
CTD |
PMID:10723097 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] |
CTD |
PMID:26072274 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
decreases activity |
ISO |
Adenosine Triphosphate results in decreased activity of ENPP7 protein |
CTD |
PMID:12885774 |
|
NCBI chr10:108,095,131...108,099,483
Ensembl chr10:108,095,131...108,099,483
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:25440059 |
|
NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
|
|
G |
F2 |
coagulation factor II |
multiple interactions increases transport increases abundance increases secretion |
ISO |
calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] F2 protein results in increased transport of Adenosine Triphosphate STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:2030746 PMID:15342215 PMID:30696774 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:26670611 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:10723097 PMID:19463813 PMID:27466191 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases secretion |
ISO EXP |
oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] NCS1 protein promotes the reaction [Adenosine Triphosphate results in increase |